Related Experiment Video
Updated: Jun 1, 2026
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
Antitumor activity of NRC-AN-019 in a pre-clinical breast cancer model
Christopher S Gondi1, Bharathi Gorantla, A K S Bhujanga Rao
1Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, Peoria, IL, USA.
Abstract:
Breast cancer is the second most frequently diagnosed tumor in women. Overexpression of human epidermal growth factor receptors (EGFRs) represents a biological subclass of breast cancer with distinct molecular alterations, clinical behavior and response to systemic therapy. In this study, we describe a novel compound (NRC-AN-019), which has better antitumor activity than Lapatinib. Here, we demonstrate that NRC-AN-019 is more effective in inhibiting angiogenic potential and proliferation of both MDAMB231 and HTB20/BT474 cells. FACS analysis shows that NRC-AN-019 treatment caused the accumulation of MDAMB231 and BT474 cells in the sub G0/1 phase in a dose-dependent manner and was accompanied by increased PARP cleavage, which is indicative of apoptosis. In addition, we observed inhibition of EGFR phosphorylation in both MDAMB231 and BT474 cells. From our animal studies using SCID mice implanted with BT474 cells, we observed dose-dependent inhibition of tumor growth in NRC-AN-019-treated animals compared to controls or Lapatinib-treated mice at comparable concentrations. The dose-dependent inhibition of EGFR phosphorylation was confirmed by immunohistochemical analysis of tumor sections. In vitro results demonstrate that NRC-AN-019 is superior to Lapatinib in EGFR-overexpressing cells and has strong anti-angiogenic, anti-proliferative and pro-apoptotic properties in an EGFR-overexpressing background (BT474). In vivo studies demonstrate that the antitumor activity of NRC-AN-019 is better over Lapatinib. These results suggest that NRC-AN-019 has greater therapeutic potential in the treatment of Her-2-positive breast cancer.
Insights
A new compound, NRC-AN-019, shows superior antitumor activity against EGFR-overexpressing breast cancer cells compared to Lapatinib. It effectively inhibits proliferation, angiogenesis, and promotes apoptosis, with promising in vivo results.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Breast cancer is a leading cancer in women, with a subset overexpressing human epidermal growth factor receptors (EGFRs).
- EGFR-overexpressing breast cancers exhibit unique molecular profiles and treatment responses.
- Lapatinib is a targeted therapy for certain breast cancers, but novel agents are needed.
Purpose of the Study:
- To evaluate the efficacy of a novel compound, NRC-AN-019, against EGFR-overexpressing breast cancer cells.
- To compare the anti-tumor, anti-angiogenic, anti-proliferative, and pro-apoptotic effects of NRC-AN-019 with Lapatinib.
- To assess the in vivo therapeutic potential of NRC-AN-019 in a preclinical breast cancer model.
Main Methods:
- In vitro studies using MDAMB231 and HTB20/BT474 cell lines to assess proliferation, apoptosis (via FACS and PARP cleavage), and EGFR phosphorylation.
- In vivo studies using SCID mice xenografted with BT474 cells to evaluate tumor growth inhibition and EGFR phosphorylation via immunohistochemistry.
- Comparative analysis of NRC-AN-019 and Lapatinib efficacy at comparable concentrations.
Main Results:
- NRC-AN-019 demonstrated superior inhibition of angiogenic potential and proliferation in both cell lines compared to Lapatinib.
- FACS analysis revealed dose-dependent accumulation of cells in sub-G0/1 phase and increased PARP cleavage, indicating apoptosis induction by NRC-AN-019.
- NRC-AN-019 effectively inhibited EGFR phosphorylation in vitro and in vivo, with superior antitumor activity observed in mouse models.
- In vivo studies showed dose-dependent tumor growth inhibition in NRC-AN-019 treated mice, outperforming Lapatinib.
Conclusions:
- NRC-AN-019 exhibits potent anti-angiogenic, anti-proliferative, and pro-apoptotic properties in EGFR-overexpressing breast cancer cells.
- The novel compound NRC-AN-019 demonstrates superior therapeutic potential compared to Lapatinib for Her-2-positive breast cancer.
- NRC-AN-019 warrants further investigation as a potential therapeutic agent for Her-2-positive breast cancer.
